Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 552

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 552
---
 | ​ | ​    
 2023 | ​ | ​ 
 ​ 
 ​ | ​        
 ​        
 % change 
 ​        |
|:-------------------------------------------------------------------------------------------|:--|:----------------------------|------:|:--|:-----|:--|:--|:---------|:--|:----------------------------|------:|:--|:-----|:--|:--|:---------|
| Non-cash interest expense on liability related to sales of future royalties and milestones | ​ | $                           | 1,960 | ​ | $    | — |   | N/A      | ​ | $                           | 5,852 | ​ | $    | — |   | N/A      |

Cara recognized $2.0 million and $5.9 million of non-cash interest expense on the liability related to sales of future royalties and milestones for the three and nine months ended September 30, 2024, respectively, which represented imputed interest on the carrying value of the liability to HCR, and the amortization of the related issuance costs associated with the Original HCR Agreement. There was no non-cash interest expense on liability recognized during the three and nine months ended September 30, 2023 as the Original HCR Agreement was entered into in the fourth quarter of 2023 (see “ — Royalty Purchase and Sale Agreement” above). Comparison of the Years Ended December 31, 2023 and 2022 Revenue

| ​                          
 ​                          
 ​                          
 ​                          | ​ 
 ​ 
 ​ | ​                           
 2023                        
 Dollar amounts in thousands 
 ​                           |      ​ 
      ​ | ​ |        ​ 
 % change | ​ | ​    
 2022 
 ​    |      ​ 
      ​ | ​ |        ​ 
 % change | ​ |
|:---------------------------|:--|:----------------------------|-------:|:--|---------:|:--|:-----|-------:|:--|---------:|:--|
| Collaborative revenue      | ​ | $                           | 12,936 | ​ |      -22 | % | $    | 16,572 | ​ |    2,248 | % |
| Commercial supply revenue  |   | ​                           |  5,843 |   |      -43 | % | ​    | 10,223 |   |    1,358 | % |
| License and milestone fees |   | ​                           |    910 |   |      -94 |